These cells have historically been identified by the presence of a protein called CD34. HSCs that express this surface marker ...

Addressing investors at the 42nd Annual J.P. Morgan Healthcare Conference, Gottesdiener said Prime Medicine supported its IND ...

Takara Bio’s dissolvable, microfluidic gene delivery enhancer transforms viral transduction to enable advances in cell and gene therapy research.

Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial ...

SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

The researchers obtained similar results when they examined the transcriptome of let-7 low and let-7 high CD34+ hematopoietic ...

Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals. Read more ...

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report), retaining ...

and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

In this GEN webinar, Aaron Rose, PhD, explores how biological therapeutics are reshaping the traditional drug development process and why humanized models are essential for advancing biologics ...